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3 Purpose of document 
 
This document presents additional information on the validation of QFracture compared 
with FRAX based on data presented in the original BMJ paper from 2009. It has been 
prepared by Professor Julia Hippisley-Cox and Dr Carol Coupland for NICE following an email 
from Sylvia Rabar, Senior Project Manager and Research Fellow in relation to a clinical 
guideline, in the UK, commissioned by the National Institute for Health and Clinical 
Excellence (NICE), on risk assessment for fragility fracture. See the appendix for a copy of 
the email. 
 
The NICE guidance information can be found here. 
 
http://guidance.nice.org.uk/CG/Wave25/2  
  
 
4 Aims and objective 
 
The overall aim is to examine sensitivity and specificity of FRAX and QFracture at different 
thresholds for osteoporotic fracture and hip fractures.  
The objectives are  
 to compare the ROC curve data for QFracture and FRAX when applied to the 
QResearch database  
 To compare the sensitivity, specificity (together with True positive, true negative, 
false positive and false negative values) for the following thresholds: 
- Major osteoporotic fractures: 10%, 20% and 30% 
- Hip fractures: 3% and 5% 
 
5 Background 
 
In 2009, Hippisley-Cox and Coupland published a paper describing the development and 
validation of QFracture1 – a set of risk prediction algorithms to predict 10 year risk of hip 
fracture and osteoporotic fracture (hip, vertebral, or distal radius fracture) in primary care. 
The algorithms were developed using data from a sample of two thirds of practices in the 
QResearch database and validated using the remaining third so that the validation sample is 
physically separate from the derivation sample. QResearch is a database derived from 
general practices using the EMIS clinical system (EMIS is the clinical system used by more 
than 55% of GP practices nationally).  The resulting publically available web calculator and 
open source software can be found at www.qfracture.org . As part of the original study, we 
calculated FRAX scores for hip fracture using an automated call to the FRAX website in Nov 
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2008 so that a comparison could be made between QFracture and FRAX for hip fracture. 
The resulting FRAX scores were then used for the analyses reported in the BMJ paper.  
In 2010, however, the authors tried to obtain FRAX scores using the same automated 
procedure for a second time and found that there were significant discrepancies between 
the FRAX scores generated by the FRAX website in 2008 (and used for the BMJ paper) and 
those generated by the FRAX website in 2010 for the same input data. It was not possible to 
determine if this was an intended change to FRAX, a bug in the underlying algorithm or a 
bug in the FRAX software implementing the algorithm or a combination of all three. Since 
the FRAX algorithm(s) is unpublished we contacted the FRAX developers. Disappointingly 
they have not been able to respond and have since disabled the web facility which allowed 
calculation of FRAX scores for large datasets. It is therefore safest to assume that the 
validation of FRAX reported in the 2009 BMJ paper is a historical validation of a previous 
version of the FRAX algorithm rather than a validation of the current FRAX algorithm2.  
 
In 2011, Collins, Mallet and Altman published an independent external validation of 
QFracture in the BMJ3. This validation study tested the performance of QFracture on a 
separate cohort of patients contributing to the THIN database. The THIN database is a 
primary care database derived from general practices using the Vision clinical system. The 
Vision clinical system is the second most commonly used GP computer system since it is 
used by 20% of GP practices nationally. The authors had intended to compare QFracture 
directly to FRAX but report they were unable to do this since the FRAX algorithm is 
unpublished and not available from the authors.  
 
In this report, we summarise existing published information on the validation of QFracture 
and FRAX and report additional analyses using QFracture and FRAX based on the QResearch 
database. The FRAX scores used throughout this report are based on 2008 scores, obtained 
using the version that does not incorporate bone mineral density. A summary of the 
differences in the variables included in FRAX and QFracture can be found in the appendix.  
 
6 Methodology 
 
The methods have been reported in detail in the original paper1 but are summarised here 
for ease of reference. Both in the original paper and the independent external validation by 
Collins and Altman3, the primary measures of statistical performance are R2(an estimate of 
variation in time to outcome explained by the risk score)4 and the D statistic (a measure of 
discrimination where higher values indicate better discrimination)5 as these take account of 
the survival nature of the data. ROC values were calculated as a rough guide and for 
comparison with other studies but the ROC statistic is not really appropriate for survival 
data since it assumes all patients have at least 10 years of follow up data (which is not 
always the case).    
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7 Results 
 
7.1 QFracture vs. FRAX using the QResearch database 
 
The first table shows the results from the validation of QFracture in patients aged 30-85 
years using the validation cohort from the QResearch database. These are reproduced from 
the  2009 BMJ paper1.  
 
Table 1  Validation statistics for osteoporotic fracture using QFracture based on the QResearch 
validation cohort in patients aged 30-85.  
 
 QFracture QFracture 
 Osteoporotic fracture 
30-85 years 
Hip fracture 
30 to 85 years 
Women   
R2 (%) 44.87 (43.07 to 46.67) 63.94 (62.12 to 65.76) 
D Statistic 1.85 (1.78 to 1.91) 2.73 (2.62 to 2.83) 
ROC statistic 0.788 (0.786 to 0.790) 0.890 (0.889 to 0.892) 
   
Men   
R2 (%) 30.03 (22.21 to 37.84) 63.19 (60.81 to 65.57) 
D statistic 1.34 (1.09 to 1.59) 2.68 (2.55 to 2.82) 
ROC statistic 0.692 (0.683 to 0.701) 0.856 (0.851 to 0.860) 
« Prev 
Close 
The next table shows the performance of QFracture for predicting hip fracture when applied to 
patients aged 40-85 so that it can be directly compared with FRAX (which can only be applied to 
patients aged 40-85 years). Overall, QFracture performed better than FRAX.  For example, QFracture 
explained 57.3% of the variation in time to fracture for women aged 40-85 years compared with 
54.8% for FRAX.  
Table 2   Validation statistics for hip fracture using QFracture based on the QResearch validation 
cohort in patients aged 40-85 years 
 QFracture FRAX 
 Hip fracture 
40-85 years 
Hip fracture 
40-85 years 
Women   
R2 (%) 57.29 (57.18 to 58.09) 54.83 (54.43 to 55.12) 
D Statistic 2.37 (2.32 to 2.42) 2.26 (2.21 to 2.30) 
ROC statistic 0.846  (0.841 to 0.850) 0.845 (0.840 to 0.849) 
   
Men   
R2 (%) 57.67 (56.78 to 58.57) 54.08 (52.10 to 53.65) 
D statistic 2.39 (2.30 to 2.48) 2.22 (2.14 to 2.30) 
ROC statistic 0.820 (0.809 to 0.831) 0.817 (0.806 to 0.828) 
« Prev 
Close 
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7.2 Independent external validation of QFracture on THIN 
 
The next table summarises the performance statistics of QFracture for hip and osteoporotic 
fracture on THIN as reported by Collins et al in the BMJ3. This shows that the performance of 
QFracture on the external THIN dataset was comparable to that on the QResearch database.  
Indeed, the performance for the osteoporotic fracture outcome was better on THIN than 
QResearch. The authors comment that no comparison with FRAX was possible as the 
algorithm was unavailable3. 
 
Table 3  Validation statistics for hip fracture and osteoporotic fracture using QFracture based on 
the THIN validation cohort in patients aged 30-85.  
 QFracture on THIN 
database 
QFracture on THIN 
database 
 Osteoporotic fracture Hip fracture 
Women   
R2 49.24 (48.64 to 49.85) 62.82 (62.22 to 63.43) 
D Statistic 2.02 (1.99 to 2.04) 2.66 (2.63 to 270) 
ROC statistic 0.816 0.890 
   
Men   
R2 37.99 (36.64 to 39.35) 60.42 (59.22 to 61.63) 
D statistic 1.60 (1.56 to 1.65) 2.53 (2.46 to 2.59) 
ROC statistic 0.739 0.855 
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7.3 Calibration of QFracture and FRAX(2008) in patients aged 40-85 
years.  
 
As reported in the BMJ paper, for QFracture, there was close correspondence between predicted 
and observed 10 year risks within each model tenth. For example, in the top tenth of risk for women, 
the mean predicted 10 year risk of hip fracture for QFracture was 9.87% and the observed risk was 
9.40%. The ratio of predicted to observed risk in this tenth was 1.05 indicating almost perfect 
calibration (a ratio of 1 indicates perfect calibration i.e. no under-prediction or over-prediction).  
For FRAX (2008), however, there was over prediction of risk for men and women in every tenth as 
shown in the table. 
Table 4: Predicted and observed risks for hip fracture at 10 years in patients aged 40-85 years by 
tenth of predicted risk using the QFracture and FRAX (2008) scores.  
Women Hip Fracture  
QFracture 
Hip Fracture  
FRAX® 
tenth§ Mean 
predicted 
risk (%) 
observed 
risk (%) 
ratio 
predicted/ 
observed 
Mean 
predicted 
risk (%) 
observed 
risk (%) 
ratio 
predicted/ 
observed 
1 0.05 0.02 2.47 0.16 0.08 2.03 
2 0.08 0.10 0.81 0.16 0.08 2.03 
3 0.12 0.14 0.86 0.30 0.17 1.76 
4 0.18 0.14 1.30 0.40 0.25 1.60 
5 0.29 0.32 0.90 0.54 0.33 1.65 
6 0.51 0.47 1.08 0.83 0.61 1.36 
7 0.97 1.03 0.95 1.37 1.06 1.29 
8 2.01 1.98 1.01 2.46 1.99 1.24 
9 4.14 4.30 0.96 4.74 4.34 1.09 
10 9.87 9.40 1.05 10.07 9.33 1.08 
   
men Hip Fracture 
QFracture 
Hip fracture  
FRAX® 
tenth§ Mean 
predicted 
risk (%) 
observed 
risk (%) 
ratio 
predicted/ 
observed 
Mean 
predicted 
risk (%) 
observed 
risk (%) 
ratio 
predicted/ 
observed 
1 0.04 0.04 1.04 0.10 0.06 1.66 
2 0.06 0.06 1.02 0.10 0.06 1.66 
3 0.08 0.08 1.01 0.20 0.11 1.82 
4 0.11 0.07 1.53 0.20 0.11 1.82 
5 0.14 0.15 0.96 0.30 0.17 1.76 
6 0.21 0.19 1.09 0.40 0.24 1.67 
7 0.32 0.34 0.94 0.59 0.34 1.72 
8 0.56 0.46 1.21 0.98 0.52 1.88 
9 1.16 1.38 0.84 1.76 1.36 1.30 
10 4.12 3.39 1.21 3.87 3.31 1.17 
§ represents  tenth of predicted risk  
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7.4 ROC curve for QFracture on QResearch 
 
The receiver operator curves (ROC) for QFracture for both outcomes based on the original 
QResearch validation cohort are shown below. Separate curves are shown for women and 
men aged 30-85 years. ROC curves are also shown for FRAX for hip fracture in women and 
men aged 40-85.  
 
Tables giving the sensitivity, specificity positive and negative predictive values at predefined 
thresholds can be found in the following section.  
 
The ROC curves show higher areas under the curve for hip fracture than osteoporotic 
fracture, and higher values for women than men.  
 
 
Figure 1  ROC curve for QFracture for osteoporotic fracture in women aged 30-85  
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Figure 2 ROC curve for QFracture for hip fracture in women aged 30-85  
 
 
Figure 3 ROC curve for QFracture for osteoporotic fracture in men aged 30-85  
 
  
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
s
it
iv
it
y
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.8889
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
s
it
iv
it
y
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.6919
Validation of QFracture and FRAX for NICE 2011   
©Julia Hipisley-Cox, University of Nottingham, 2011. 
 Page 7-11 
 
Figure 4 ROC curve for QFracture for hip fracture in men aged 30-85  
 
 
Figure 5 ROC curve for FRAX for hip fracture in women aged 40-85  
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Figure 6 ROC curve for FRAX for hip fracture in men aged 40-85  
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7.5 Sensitivity and specificity of QFracture ages 30-85 years 
 
The next table show the sensitivity, specificity, positive and negative predictive values at 
pre-selected thresholds of 10 year risk for QFracture for hip fracture and major fractures 
(comprising hip, vertebral, and distal radius fractures)  It includes all patients (even if 
censored before 10 years). 
 
For example, if a cut off of a 10 year risk of 3% for hip fracture in women is used, then it will 
identify 13.1% of women aged 30-85 as high risk. This will then contain 64.1% of all cases of 
hip fracture in the next 10 years will be identified (i.e. sensitivity of 64.1%). The positive 
predictive value is 4% meaning that for every 100 women selected in this high risk group, 
then 4 are likely to have a hip fracture over the next 10 years. If the threshold is increased to 
5%, then the sensitivity will fall to 46.8% but the positive predictive value will increase to 
4.6% and the specificity will increase to 92%. 
 
Table 5  sensitivity, specificity, positive predictive value and negative predictive value of 
QFracture for hip fracture and major fracture at selected thresholds of 10 year risk. Analysis of all 
patients 30-85 years. 
 
 cut off* 
(%) 
Total
% 
identif
ied as 
high 
risk 
true 
negative 
false 
negative 
false 
positive 
True 
positiv
e 
sensit
ivity 
specif
icity 
PPV NPV 
Women           
hip fracture 3% 13.3 562,941 1,948 83,463 3,476 64.1 87.1 4.0 99.7 
hip fracture 5% 8.4 593,975 2,887 52,429 2,537 46.8 91.9 4.6 99.5 
major fracture 10% 7.7 582,257 10191 45,567 3,761 27.0 92.7 7.6 98.3 
major fracture 20% 0.5 624,773 13640 3,051 312 2.2 99.5 9.3 97.9 
major fracture 30% 0.1 627,500 13916 324 36 0.3 99.9 10.0 97.8 
Men           
hip fracture 3% 3.6 615,500 1325 22787 413 23.8 96.4 1.8 99.8 
hip fracture 5% 1.6 628,457 1529 9830 209 12.0 98.5 2.1 99.8 
major fracture 10% 0.2 627,723 4464 1445 55 1.2 99.8 3.7 99.3 
major fracture 20% 0.0 629,102 4515 66 4 0.1 100.0 5.7 99.3 
major fracture 30% 0.0 629,163 4518 5 1 0.0 100.0 16.7 99.3 
All            
hip fracture 3% 8.5 1,178,441 3,273 106,250 3,889 54.3 91.7 3.5 99.7 
hip fracture 5% 5.0 1,222,432 4,416 62,259 2,746 38.3 95.2 4.2 99.6 
major fracture 10% 4.0 1,209,980 14,655 47,012 3,816 20.7 96.3 7.5 98.8 
major fracture 20% 0.3 1,253,875 18,155 3,117 316 1.7 99.8 9.2 98.6 
major fracture 30% 0.03 1,256,663 18,434 329 37 0.2 100.0 10.1 98.6 
*10 year risk of outcome calculated using QFracture(%) 
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Note that caution must be taken when interpreting the statistics in these tables, since they 
do not differentiate patients who were censored before 10 years (eg because of death or 
the end of the study) and so we do not know the eventual outcome for these patients. The 
effect of this is to under-estimate the positive predictive values. 
 
7.6 Sensitivity and specificity of QFracture ages 40-85 years 
 
The next QFracture table is similar to the previous table in what it reports except it applies 
to patients aged 40-85 years. 
 
Table 6  sensitivity, specificity, positive predictive value and negative predictive value of 
QFracture for hip fracture and major fracture at selected thresholds of 10 year risk. Analysis 
includes all patients 40-85 years. 
 
 cut off 
*(%) 
% high 
risk 
true 
negative 
false 
negative 
false 
positive 
True 
positiv
e 
sensiti
vity 
specifi
city 
PPV NPV 
Women           
hip fracture 3 19.1 365,682 1,918 83,463 3,476 64.4 81.4 4.0 99.5 
hip fracture 5 12.1 396,716 2,857 52,429 2,537 47.0 88.3 4.6 99.3 
major fracture 10 11.1 386906 9513 45567 3761 28.3 89.5 7.6 97.6 
major fracture 20 0.8 429422 12962 3051 312 2.4 99.3 9.3 97.1 
major fracture 30 0.1 432149 13238 324 36 0.3 99.9 10.0 97.0 
Men           
hip fracture 3 5.5 399875 1261 22787 413 24.7 94.6 1.8 99.7 
hip fracture 5 2.4 412832 1465 9830 209 12.5 97.7 2.1 99.6 
major fracture 10 0.4 415053 3766 1445 55 1.4 99.7 3.7 99.1 
major fracture 20 0.0 416432 3817 66 4 0.1 100.0 5.7 99.1 
major fracture 30 0.0 416493 3820 5 1 0.0 100.0 16.7 99.1 
All            
hip fracture 3 12.5 765,557 3,179 106,250 3,889 55.0 87.8 3.5 99.6 
hip fracture 5 7.4 809,548 4,322 62,259 2,746 38.9 92.9 4.2 99.5 
major fracture 10 5.9 801,959 13,279 47,012 3,816 22.3 94.5 7.5 98.4 
major fracture 20 0.4 845,854 16,779 3,117 316 1.8 99.6 9.2 98.1 
major fracture 30 0.04 848,642 17,058 329 37 0.2 100.0 10.1 98.0 
*10 year risk of outcome calculated using QFracture(%) 
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7.7 Sensitivity and specificity of FRAX (2008) ages 40-85 years 
 
The next table is similar to the previous table but is based on FRAX (2008) instead of 
QFracture and only includes hip fracture (the FRAX risk score for fracture was not included 
in the original BMJ paper as the outcome definition was different).  
 
Using a cut off for women of 3% for the FRAX score, would identify 21.6% of women aged 
40-85 at risk compared with 19.1% for QFracture. Using the 5% threshold would identify 
13.9% at risk using FRAX but 12.1% using QFracture. In other words if pre-defined 
thresholds are used then this will identify large number of patients with FRAX compared 
with QFracture 
 
 Table 7  sensitivity, specificity, positive predictive value and negative predictive value of FRAX 
(2008) for hip fracture at selected thresholds of 10 year risk. Analysis includes all patients 40-85 
years. 
 
 cut 
off 
*(%) 
% high 
risk 
true 
negativ
e 
false 
negat
ive 
false 
positiv
e 
True 
positiv
e 
sensiti
vity 
specifi
city 
PPV NPV 
Women           
hip fracture 3 21.6 354,655 1,652 94,451 3,741 69.4 79.0 3.8 99.5 
hip fracture 5 13.9 388,921 2,570 60,185 2,823 52.3 86.6 4.5 99.3 
Men           
hip fracture 3 6.9 393717 1166 28945 508 30.3 93.2 1.7 99.7 
hip fracture 5 1.6 416108 1540 6554 134 8.0 98.4 2.0 99.6 
All            
hip fracture 3 14.5 748,372 2,818 123,39
6 
4,249 60.1 85.8 3.3 99.6 
hip fracture 5 7.9 805,029 4,110 66,739 2,957 41.8 92.3 4.2 99.5 
*10 year risk of outcome calculated using FRAX(%) 
 
 
 
  
Validation of QFracture and FRAX for NICE 2011   
©Julia Hipisley-Cox, University of Nottingham, 2011. 
 Page 7-16 
 
7.8 Sensitivity and specificity using deciles of predicted risks 
 
Given that FRAX (2008) over predicts risk of hip fracture compared with observed risks (as 
shown by the ratio of predicted to observed risks in the previous section), the use of pre-
defined thresholds does not give a direct comparison between the two scores. To make a 
direct comparison, we have therefore repeated the analysis based on the top 10% and top 
20% of predicted risk for each score, to give equivalent numbers of people in high risk 
groups.   
 
The next table shows the results of the direct comparison between QFracture and FRAX and 
shows that the sensitivity of QFracture is similar or slightly higher than that for FRAX for 
men and women when comparison high risk groups of the same size. For example, for men 
the cut off for the top decile was a 10 year risk of 1.8% using QFracture and 2.4% for FRAX.  
The sensitivity at this threshold for men using QFracture was 41.1% compared with 39.0% 
for FRAX.  
 
Table 8 Direct comparison between QFracture and FRAX (2008) for patients in the top 10% 
and 20% of predicted risk of hip fracture using each algorithm for men and women.  
 
QFracture cut 
off 
*(%) 
true 
negative 
false 
negative 
false 
positive 
True 
positive 
sensitivity specificity 
  TN FN FP TP   
Women        
top 20% 2.8% 361,775 1,826 87,331 3,567 66.1 80.6 
top 10% 5.8% 405,823 3,228 43,283 2,165 40.1 90.4 
Men        
top 20% 0.8% 338,915 555 83747 1119 66.8 80.2 
top 10% 1.8% 380,918 986 41744 688 41.1 90.1 
 
FRAX cut 
off 
*(%) 
true 
negative 
false 
negative 
false 
positive 
True 
positive 
sensitivity specificity 
  TN FN FP TP   
Women        
top 20% 3.3% 363,222 1,841 85,884 3,552 65.9 80.9 
top 10% 6.4% 406,496 3,233 42,610 2,160 40.1 90.5 
Men        
top 20% 1.2% 339,346 567 83316 1107 66.1 80.3 
top 10% 2.4% 383,263 1021 39399 653 39.0 90.7 
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8 Re-classification statistics 
 
For the next analysis, we define high risk a 10 year risk of hip fracture in the top tenth for 
each risk score. We then looked at how many patients would be re-classified using 
QFracture compared with FRAX. The results are shown in the table below.  
 
For example, for women, then using the top decile for each score, then 88.9% are classified 
classifed as low risk by both scores and 8.8% are classified as high risk by both scores. 1.2% 
of women would be classified as high risk on QFracture and low risk on FRAX and the 
observed 10 year risk in these women was 7.69%. Conversely, 1.1% of women would be 
classified as low risk on QFracture but high risk on FRAX. The observed 10 year risk in these 
women was 7.15%. In other words, women who would be missed’ as high risk if FRAX were 
used, had a higher observed risk than women who would be ‘missed’ as high risk if 
QFracture were used. There were similar findings in men 
 
Table 9: reallocation of patients based on using top decile of risk for each score. Figures are 
counts(%) and 10 year observed risks calculated using Kaplan Meier plots 
 
 numbers % of 
total 
10 yr observed risk 
women    
low on both QFracture and FRAX 404105 88.9 0.88 
low on FRAX high on QFracture 5624 1.2 7.69 
high on FRAX low on QFracture 4946 1.1 7.15 
high on both QFracture and FRAX 39824 8.8 9.66 
total 454499 100.0  
    
Men     
low on both QFracture and FRAX 377954 89.1 0.09 
low on FRAX high on QFracture 6330 1.5 2.24 
high on FRAX low on QFracture 3950 0.9 1.45 
high on both QFracture and FRAX 36102 8.5 3.63 
total 424336 100.0  
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9 Summary of main findings 
 
We have presented a direct comparison between QFracture and FRAX based on the same 
population with the following conclusions: 
 
 QFracture performs better than FRAX (2008) with better discrimination.  
 QFracture is well calibrated whereas FRAX (2008) over-predicts risk in every tenth of 
risk.  
 QFracture has similar sensitivity compared with FRAX(2008) for men and women 
when the top decile of risk is identified. 
 QFracture also performed well on an independent external dataset using data from 
the THIN database. Some of the performance statistics were better on the THIN 
dataset than the separate sample of practices used for the validation from 
QResearch.  
 The current version of FRAX (2011) does not match the version of FRAX from 2008, 
so the comparisons made in this paper are with a historical version of FRAX and it is 
not possible to determine comparisons with a current version of FRAX.  
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11 Appendix 1- variables included in QFracture compared 
with FRAX 
 
 Included in QFracture Included in FRAX 
Age range 30-85 40-90 
Sex Yes, separate models men 
and women 
Yes as variable in one model 
Smoking status 5 levels  - non, ex smoker, 
light, moderate, heavy 
smoker 
Yes as binary variable 
Alcohol Yes 5 categories Yes as binary variable 
Body mass index Yes Yes 
Family history of osteoporosis yes Yes 
Rheumatoid arthritis Yes  Yes 
Type 2 diabetes Yes Type 1 included within 
secondary osteoporosis 
Regular steroids Yes Yes 
Chronic liver disease Yes Included within secondary 
osteoporosis 
Malabsorption (crohn’s, 
ulcerative colitis, coeliac 
disease, blind loop) 
Yes Included within secondary 
osteoporosis 
Other endocrine disorders 
(thyrotoxicosm, cushing’s 
hyperparathyroidism,) 
Yes Hyperthyroidism included 
within secondary 
osteoporosis 
HRT Yes (women only) no 
Cardiovascular disease Yes no 
History of falls Yes No 
Menopausal symptoms (flushes 
or vaginal dryness) 
yes No 
Asthma Yes no 
Tricyclic antidepressants Yes No 
Previous fracture No  yes 
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12 Appendix 2- request from NICE 
From: Silvia Rabar [mailto:Silvia.Rabar@rcplondon.ac.uk]  
Sent: 02 November 2011 10:01 
To: julia.hippisley-cox@nottingham.ac.uk 
Subject: Information request 
 
Dear Dr Hippisley-Cox,  
I am writing to ask you for more information related to your publication in BMJ 2009; 
339:b4229, entitled “Predicting risk of osteoporotic fracture in  men and women in England 
and Wales: prospective derivation  and validation of QFracture scores””.  
We are currently developing a clinical guideline, in the UK, commissioned by the National 
Institute for Health and Clinical Excellence (NICE), on risk assessment for fragility fracture  
http://guidance.nice.org.uk/CG/Wave25/2  
I understand from your paper you have performed a subgroup analysis to compare FRAX (I 
believe you used the version FRAX without BMD, as  opposed to FRAX with BMD) to 
QFracture, and you have reported the ROC value for the FRAX algorithm. One of our aim is 
to compare sensitivity and specificity of FRAX (both with and without BMD, where available) 
and QFracture at different thresholds for osteoporotic fractures and hip fractures. 
Therefore, it would be very helpful for our purposes if you could send me the ROC curve 
data, point by point, for both FRAX (without BMD?) and QFracture, applied to the same 
population. If this is not possible, would you be able to send me at least sensitivity, 
specificity (together with True positive, true negative, false positive and false negative 
values) for the following thresholds: 
 
- Major osteoporotic fractures: 10%, 20% and 30% 
- Hip fractures: 3% and 5%   
 Should you require any further information, please do not hesitate to contact me. I look 
forward to hearing from you soon.  
 
Regards, 
Silvia 
Dr Silvia Rabar 
Senior Project Manager and Research Fellow 
National Clinical Guideline Centre (NCGC) 
180 Great Portland Street 
London W1W 5QZ 
Direct line: 020 3075 1414 
Mobile: 07990 745 663 
Email: silvia.rabar@rcplondon.ac.uk 
Website: www.ncgc.ac.uk 
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